SYMBIOTEC PHARMALAB LTD (SYMBIOTEC): SYMBIOTEC Share Price rises 5.61% as stock gains today
- September 29, 2026
- Posted by: Harsh Piplani
- Category: News
SYMBIOTEC Share Price rose 5.61% to Rs 1,116 today, adding Rs 59.25 from the previous close. The company’s market capitalisation stands at Rs 6,442 Cr, and the supplied data confirms a same-day price rise without establishing a company-specific catalyst.
SYMBIOTEC Share Price moved higher on 29 September 2026, with the stock closing at Rs 1,116 after opening at Rs 1,043.10 and touching an intraday high of Rs 1,130.10. The move from the previous close of Rs 1,056.75 translated into a gain of Rs 59.25, or 5.61%, while turnover stood at Rs 9.54 Cr. The market capitalisation is Rs 6,442 Cr. The supplied data confirms the price event, but it does not establish a company-specific catalyst. For readers following SYMBIOTEC Share Price Today, the key question is what the move means against valuation, sector benchmarks and peer metrics. In this SYMBIOTEC Stock News update, Univest focuses on verified facts first, then places the move in its fundamental and sector context so the day’s price action is easier to read.
SYMBIOTEC Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 1,116 |
| Previous Close | Rs 1,056.75 |
| Today's Move | Rs 59.25 (+5.61%) |
| Open | Rs 1,043.1 |
| High | Rs 1,130.1 |
| Low | Rs 1,043.1 |
| Turnover | Rs 9.54 crore |
| Market Capitalisation | Rs 6,442 crore |
| Market Cap Category | Mid Cap |
SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) rose to Rs 1,116 from the previous close of Rs 1,056.75, a move of Rs 59.25 or 5.61%. The stock opened at Rs 1,043.1, reached a high of Rs 1,130.1, recorded a low of Rs 1,043.1.
SYMBIOTEC Share Price rose 5.61% today, with the stock trading between Rs 1,043.10 and Rs 1,130.10 during the session. The day opened at Rs 1,043.10, exactly at the intraday low, and closed at Rs 1,116, above the previous close of Rs 1,056.75. The absolute rise of Rs 59.25 and turnover of Rs 9.54 Cr show the day’s scale in factual terms. This is a clear same-day share price gain, and the supplied data confirms the event without identifying a catalyst. For investors scanning SYMBIOTEC Share Price Live or SYMBIOTEC Share Price Update, the immediate takeaway is simple: the stock ended above its opening level and above the prior close, with the day’s range remaining broad enough to keep today’s SYMBIOTEC Stock Performance in focus.
SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 6,442 crore |
| P/E Ratio | 61.78x |
| P/B Ratio | 4.53x |
| ROE | 11.22% |
| ROCE | 12.41% |
| EPS | Rs 17.1 |
| Book Value Per Share | Rs 233.38 |
| Dividend Yield | 0% |
SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) fundamental metrics show P/E 61.78x, P/B 4.53x, ROE 11.22%, ROCE 12.41%. These figures provide context only and are not a buy or sell signal.
SYMBIOTEC PHARMALAB LTD has a market capitalisation of Rs 6442 crore and falls in the Mid Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 61.78x, P/B at 4.53x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 11.22% and ROCE of 12.41%, helping investors compare shareholder returns and capital efficiency. Additional supplied metrics include EPS of Rs 17.1, book value per share of Rs 233.38, dividend yield of 0%, adding context to earnings, balance-sheet value and historical payout. Against the supplied same industry benchmark, these figures can be compared with benchmark median P/E of 32.59x, median ROE of 11.7%, median ROCE of 13.61%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 61.78x |
| Benchmark Median P/E | 32.59x |
| Benchmark Average P/E | 49x |
| Benchmark P/E Range | 3.46x to 707.31x |
| Company P/B Ratio | 4.53x |
| Benchmark Median P/B | 2.88x |
| Company ROE | 11.22% |
| Benchmark Median ROE | 11.7% |
| Company ROCE | 12.41% |
| Benchmark Median ROCE | 13.61% |
| Company Market Capitalisation | Rs 6,442 crore |
| Benchmark Median Market Cap | Rs 783.26 crore |
SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a P/E ratio of 61.78x, which is above the benchmark median of 32.59x, a difference of +89.57%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a ROE of 11.22%, which is below the benchmark median of 11.7%, a difference of -4.1%. SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a ROCE of 12.41%, which is below the benchmark median of 13.61%, a difference of -8.82%.
Track stocks leading today through the Univest top gainers screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | SUNPHARMA | 4,44,716.74 | 36.5 | 5.1 | 14.85 | 19.11 |
| Divi's Laboratories Ltd. | DIVISLAB | 2,55,115.31 | 86.51 | 14.33 | 16.19 | 21.51 |
| Torrent Pharmaceuticals Ltd. | TORNTPHARM | 1,89,613.38 | 84.92 | 20.64 | 26.76 | 19.27 |
| Zydus Lifesciences Ltd. | ZYDUSLIFE | 1,19,899.96 | 26.79 | 4.48 | 19.69 | 21.39 |
| Cipla Ltd. | CIPLA | 1,12,875.68 | 33.29 | 3.19 | 11.83 | 16 |
SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a P/E ratio of 61.78x compared with the displayed peer median of 36.5x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 11.22% compares with a peer median of 16.19% across the companies shown in the table. ROCE stood at 12.41% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a market capitalisation of Rs 6,442 crore. Among the 5 peers shown, 5 have a larger market capitalisation.
Why Investors Are Watching SYMBIOTEC
- SYMBIOTEC Share Price rose 5.61% today to Rs 1,116 after closing above the previous close of Rs 1,056.75.
- The stock’s intraday range was Rs 1,043.10 to Rs 1,130.10, which places the current SYMBIOTEC Share Price Today in the upper part of the day’s band.
- Market capitalisation stands at Rs 6,442 Cr, giving the move a clear large-capitalisation context in the supplied numbers.
- The P/E ratio is 61.78 and the P/B ratio is 4.53, both of which provide valuation context for SYMBIOTEC Fundamental Analysis.
- ROE of 11.22% and ROCE of 12.41% can be compared with the same-industry benchmark and peer set in SYMBIOTEC Stock News.
About SYMBIOTEC
SYMBIOTEC PHARMALAB LTD operates in the Healthcare sector and the Pharmaceuticals & Drugs industry. The supplied dataset does not include a business-segment breakdown, so the description remains focused on the verified industry classification and financial position. For readers tracking SYMBIOTEC Share Price, the company belongs to a sector where valuation and profitability are often read together with industry benchmarks, because peers can differ sharply on earnings multiples and return ratios. In today’s SYMBIOTEC Stock News, the company’s business identity matters mainly because it helps place the move inside the broader pharma universe rather than treating the rise as an isolated trading event. Univest presents the company in a factual frame: listed in Healthcare, classified under Pharmaceuticals & Drugs, with market cap, profitability and valuation metrics available for comparison.
Track SYMBIOTEC Share Price on Univest
Use SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top-gainers lists and related market analysis.
You can track SYMBIOTEC Share Price on Univest for live price updates, valuation ratios, market cap, shareholding pattern, sector context, 52-week levels and company insights. Univest also helps readers review SYMBIOTEC Share Price Today alongside peer comparison, financial ratios and other stock-specific data in one place. For ongoing SYMBIOTEC Stock News, the platform is designed to keep the facts organised, current and easy to compare.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why is SYMBIOTEC Share Price rising today?
Ans. The supplied data confirms a 5.61% same-day rise to Rs 1,116, but it does not establish a company-specific catalyst. Univest therefore treats the move as verified price action, not as a reason-led announcement.
What is SYMBIOTEC Share Price today?
Ans. SYMBIOTEC Share Price today is Rs 1,116. The stock gained Rs 59.25 from the previous close of Rs 1,056.75, placing the day’s move at 5.61% in the verified dataset. The previous close was Rs 1,056.75.
What is SYMBIOTEC market capitalisation?
Ans. SYMBIOTEC’s market capitalisation is Rs 6,442 Cr. That figure helps place the stock in context within the Pharmaceuticals & Drugs industry and supports a cleaner read of valuation and peer comparison.
How does SYMBIOTEC look on valuation?
Ans. SYMBIOTEC has a P/E of 61.78 and a P/B of 4.53. Both are above the same-industry median, while ROE is 11.22% and ROCE is 12.41%, which gives mixed valuation context.
How does SYMBIOTEC compare with pharma peers?
Ans. SYMBIOTEC’s P/E sits above Zydus Lifesciences, Cipla and Sun Pharma, but below Divi’s and Torrent. Its market cap is far smaller than the largest listed peers in the supplied comparison set.
Does SYMBIOTEC pay a dividend?
Ans. The dividend yield supplied for SYMBIOTEC is 0. That indicates no current yield is reflected in the dataset, so the share price discussion here stays focused on valuation and profitability.
